life scienc tool diagnost
ep miss consensu ep
estim lower revenu profit below-
ep declin midpoint vs consensu
disappoint lower ep
reduc demand china asf headwind unfavor regulatori
dynam partial off-set recent acquisit osprey biotechn
well meaning higher expens associ strateg initi
tp drop ebitda lower view
share deterior share declin latest
shortfal anem guidanc call revenu growth
includ contribut adj ebitda declin
million vs con anoth transit year
outsiz step-up sg predic invest necessari
initi support futur growth includ pipelin develop facil
expans sale forc initi new product commerci
phi-tec autom vaccin deliveri system reduc demand
china mfa repres revenu headwind asf recent
regulatori chang balanc busi expect grow
exclud osprey call commentari focu osprey contribut
underli demand trend asf outlook trade dynam fx new
develop efforts/cost share current trade ep
justifi discount diversifi industri leader risk
shift regulatori demand environ
valuat metric
number share
price month
 close
suiss seek busi compani cover research report result investor awar
firm may conflict interest could affect object report investor consid report
singl factor make invest decis
lead manufactur anim health product
concentr product anim product prevent control
treat diseas enhanc health nutrit overal
product livestock
price aug rate neutral target price analyst erin wright
profit tax
chang work capit
flow oper
free cash-flow firm
flow invest
chang net cash/debt
total liabil equiti
share wtd average
price book
roe stated-return
challeng relat antibiot use greater expect ramp
faster-grow subsector anim health vaccin nutrit
specialti favor epidemiolog weather
macroeconom trend influenc underli util trend
consider pick us intern livestock
grey sky valuat assum harsher expect
regulatori challeng global use antibiot medicin feed
addit weak global livestock demand
 close
revenu profit fall short revenu fell well plan estimate
weaker anim health vs estimate mfa deceler asf
well lower domest demand across poultri swine sector partial off-set
strength latam apac nutrit spec vs better
intern dairi partial off-set continu us dairi headwind slower growth
poultri vaccin vs plan albeit still weak loss
distribut agreement tougher econom condit partial off-set volum
certain int market gross margin rose bp bp plan
primarili mix sg rose bp bp plan drive ebitda
margin deterior bp bp short view gener million
cash cash reserv stand million
base latest disappoint result notabl lower anticip initi
target clearli continu face pressur across all-import anim health
categori weak across faster-grow profit specialti
particularli china sale vaccin decreas albeit plan
predic loss domest distribut arrang announc octob
turbul econom condit certain intern countri partial off-set
volum growth apac eastern europ meanwhil nutrit specialti rose
vs estimate volum growth intern dairi product partial off-set
domest diari headwind reduc poultri demand meanwhil mfa declin
vs estimate meaning reduct demand china relat asf
well lower domest demand poultri swine partial off-set strength
latam apac
importantli initi guidanc well short estim
consensu target revenu growth incl contribut
ep vs consensu revenu guidanc incorpor
growth current/new product acquisit osprey biotechn
partial off-set china mfa note pahc nutrit specialti vaccin
product expect return sale growth follow disappoint
experi expect adjust ebitda vs consensu impli
bp ebitda margin degrad midpoint larg predic outsiz
growth across sg invest major strateg initi support futur growth
note ebitda contribut osprey may contribut much billion
ebitda factor may fulli reflect street estim
remind announc enter agreement develop canin
lyme diseas vaccin notabl entranc faster-grow companion anim
speci segment consequ incur increment cost associ
effort along potenti develop effort partnership focus
nutrit vaccin segment across product companion anim speci
group compani target contribut effort materi longer
term make hard-hit catalyst longer term natur
charl martineau univers toronto figur quarterli revenu growth segment
anim health revenu
s/other revenu segment revenu fell well
estim meaning reduct demand china relat asf
well lower domest demand poultri swine partial off-set strength
latam apac expect sale growth mfa product ex
china asf recent regulatori develop china disproport
offset remind china ministri agricultur recent publish
implement schedul plan transit therapeut claim
medic feed addit transit expect phase
nutrit specialti revenu growth nutrit specialti
conserv estim volum growth intern dairi
product partial off-set domest diari headwind reduc poultri demand
expect nutrit specialti return growth improv
perform dairi sector follow salesforc reposit well
improv across poultri sector growth current product
recent launch provia prime direct-f microbi promot gut health
vaccin revenu vaccin sale decreas vs estimate predic
loss domest distribut arrang turbul econom condit
certain intern countri partial off-set volum growth apac
europ also expect vaccin return growth includ benefit
recent launch poultri vaccin growth also support easi
comp follow loss distribut arrang octob
turbul econom condit certain intern market
miner nutrit revenu
miner nutrit revenu view vs estimate reduc asp
unfavor product mix partial off-set increas volum miner nutrit least
profit busi expect meaning growth driver
extend histori busi industry-lead presenc extens relationship
across suppli chain help unlock cross sell opportun broader
ingredi deemphas
perform product revenu
perform product revenu growth impress vs estimate driven
increas volum person care
perform product busi past sever year expect continu
deemphas segment opportunist divestitur go forward profit
within segment remain rel low ebitda margin greater
focu higher margin anim health busi bode well profit profil
longer term
quarter gener million cash cash reserv stand
million capit deploy strategi remain focus de-lever dividend
tuck-in acquisit partnership supplement growth
earn outlook valuat
expect revenu growth reflect growth anim health
miner nutrit flat growth perform product ebitda
margin bp lower due aforement increment invest lower
revenu view along rel flat interest tax expens pursuant tax reform
contribut osprey drive ep growth
expect ep grow revenu growth
assum rel stabl fundament across us livestock industri build
momentum cross-market intern strategi forecast ebitda
margin expans bp better product mix oper effici
ep current trade premium histor averag
view unjustifi due slower growth profil price target
base multipl ep
compani mention price
